Tags

Type your tag names separated by a space and hit enter

Interferon-beta1b treatment modulates cytokines in patients with primary progressive multiple sclerosis.
Acta Neurol Scand. 2006 Dec; 114(6):368-73.AN

Abstract

OBJECTIVES

It is unknown whether the immunological effects of beta-interferon (IFN-beta) differ in primary progressive multiple sclerosis (PPMS) when compared with relapsing-remitting multiple sclerosis (RRMS). Therefore, we investigated the effects of IFN-beta1b treatment in PPMS on proliferation and cytokine pattern of peripheral blood mononuclear cells (PBMC) and interleukin-10 (IL-10) serum level.

METHODS

Eighteen patients were treated with IFN-beta1b for 12 months in an open-label trial. Serum and PBMC were collected longitudinally.

RESULTS

Interleukin-10 serum levels increased (P = 0.02) during treatment. Tumor necrosis factor-alpha was increased in anti CD3 (OKT3) antibody stimulated PBMC during treatment (P = 0.04), whereas secretion of IL-10 was decreased in OKT3 (P = 0.04), but increased in concavalin A stimulated PBMC (P = 0.02).

CONCLUSIONS

Interleukin-10 serum levels rose in IFN-beta1b-treated patients as has been observed in RRMS. The changes in cytokine patterns secreted by T-lymphocytes of PPMS patients, however, differ from effects observed in RRMS supporting the hypothesis that PPMS differs in some immunological aspects from RRMS.

Authors+Show Affiliations

Department of Neurology, University of Greifswald, Greifswald, Germany.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17083335

Citation

Dressel, A, et al. "Interferon-beta1b Treatment Modulates Cytokines in Patients With Primary Progressive Multiple Sclerosis." Acta Neurologica Scandinavica, vol. 114, no. 6, 2006, pp. 368-73.
Dressel A, Kolb AK, Elitok E, et al. Interferon-beta1b treatment modulates cytokines in patients with primary progressive multiple sclerosis. Acta Neurol Scand. 2006;114(6):368-73.
Dressel, A., Kolb, A. K., Elitok, E., Bitsch, A., Bogumil, T., Kitze, B., Tumani, H., & Weber, F. (2006). Interferon-beta1b treatment modulates cytokines in patients with primary progressive multiple sclerosis. Acta Neurologica Scandinavica, 114(6), 368-73.
Dressel A, et al. Interferon-beta1b Treatment Modulates Cytokines in Patients With Primary Progressive Multiple Sclerosis. Acta Neurol Scand. 2006;114(6):368-73. PubMed PMID: 17083335.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Interferon-beta1b treatment modulates cytokines in patients with primary progressive multiple sclerosis. AU - Dressel,A, AU - Kolb,A K, AU - Elitok,E, AU - Bitsch,A, AU - Bogumil,T, AU - Kitze,B, AU - Tumani,H, AU - Weber,F, PY - 2006/11/7/pubmed PY - 2007/1/31/medline PY - 2006/11/7/entrez SP - 368 EP - 73 JF - Acta neurologica Scandinavica JO - Acta Neurol Scand VL - 114 IS - 6 N2 - OBJECTIVES: It is unknown whether the immunological effects of beta-interferon (IFN-beta) differ in primary progressive multiple sclerosis (PPMS) when compared with relapsing-remitting multiple sclerosis (RRMS). Therefore, we investigated the effects of IFN-beta1b treatment in PPMS on proliferation and cytokine pattern of peripheral blood mononuclear cells (PBMC) and interleukin-10 (IL-10) serum level. METHODS: Eighteen patients were treated with IFN-beta1b for 12 months in an open-label trial. Serum and PBMC were collected longitudinally. RESULTS: Interleukin-10 serum levels increased (P = 0.02) during treatment. Tumor necrosis factor-alpha was increased in anti CD3 (OKT3) antibody stimulated PBMC during treatment (P = 0.04), whereas secretion of IL-10 was decreased in OKT3 (P = 0.04), but increased in concavalin A stimulated PBMC (P = 0.02). CONCLUSIONS: Interleukin-10 serum levels rose in IFN-beta1b-treated patients as has been observed in RRMS. The changes in cytokine patterns secreted by T-lymphocytes of PPMS patients, however, differ from effects observed in RRMS supporting the hypothesis that PPMS differs in some immunological aspects from RRMS. SN - 0001-6314 UR - https://www.unboundmedicine.com/medline/citation/17083335/Interferon_beta1b_treatment_modulates_cytokines_in_patients_with_primary_progressive_multiple_sclerosis_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0001-6314&date=2006&volume=114&issue=6&spage=368 DB - PRIME DP - Unbound Medicine ER -